Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BID | P55957 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176186 | 0.91 | CA12 (0.52) | CA12CA9CA2CTSLACLY | |
| SCHEMBL10176320 | 0.90 | CA12 (0.51) | CA12CA9CA2CTSLACLY | |
| SCHEMBL13790752 | 0.83 | CA12 (0.44) | CA12CA9CA2CTSLACLY | |
| SCHEMBL6867245 | 0.82 | CA12 (0.54) | CA12CA9CA2RECQLPPARG | |
| SCHEMBL3558164 | 0.82 | CA12 (0.78) | CA12CA9CA2ACLYRECQL | |
| SCHEMBL28890855 | 0.78 | NOD1 (0.55) | CA12CA9CA2PPARGPPARA | |
| SCHEMBL3433282 | 0.77 | CA12 (0.60) | CA12CA9CA2CTSLACLY | |
| SCHEMBL425798 | 0.76 | CA12 (0.58) | CA12CA9CA2ACLYRECQL | |
| SCHEMBL10176172 | 0.76 | CA12 (0.58) | CA12CA9CA2CTSLACLY | |
| SCHEMBL428054 | 0.75 | CA12 (0.57) | CA12CA9CA2CTSLACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| CN-101932569-A | Indoles, its derivative and analogue and uses thereof | UNIV OHIO STATE RES FOUND | 2010-12-29 | — | — | CN | disclosed |
| EP-2222659-A1 | INDOLES, DERIVATIVES, AND ANALOGS THEREOF AND USES THEREOF | The Ohio State University Research Foundation (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090142832-A1 | Indoles, Derivatives, and Analogs Thereof and Uses Therefor | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-04 | — | — | US | disclosed |
| US-20090142832-A1 | Indoles, Derivatives, and Analogs Thereof and Uses Therefor | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-04 | — | — | US | disclosed |
| US-20090142832-A1 | Indoles, Derivatives, and Analogs Thereof and Uses Therefor | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-04 | — | — | US | disclosed |
| WO-2009070645-A1 | INDOLES, DERIVATIVES, AND ANALOGS THEREOF AND USES THEREOF | THE OHIO UNIVERSITY RESEARCH FOUNDATION (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070645-A1 | INDOLES, DERIVATIVES, AND ANALOGS THEREOF AND USES THEREOF | THE OHIO UNIVERSITY RESEARCH FOUNDATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | TUBB, TUBB3, TUBB1 | CA12 4374/4885CA9 4149/4885CA2 4012/4885 |
| US-20090142832-A1 | Indoles, Derivatives, and Analogs Thereof and Uses Therefor | TUBB, TUBB1, TUBB6 | CA12 4715/4885CA9 4728/4885CA2 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.